Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?

Does the presence of variable staining for HER2 amongst the different components of a uterine carcinosarcoma affect your decision about the use of trastuzumab?

• Yes, I would only add trastuzumab if the HER2 is positive throughout the tumor
• No, I would add trastuzumab if any component of the tumor stains positive for HER2
• I do not use trastuzumab for uterine carcinosarcomas, regardless of HER2 status
• Other